Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lieberman

Showing results (331-340 of 345) with videos related to

Pageof 35
Sort By:
Frontiers in Immunology|May 24, 2021
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in GlioblastomaItay Raphael, Rajeev Kumar, Lauren H McCarl, et al.
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2016
Quantitative Imaging in Cancer Clinical TrialsThomas E Yankeelov, David A Mankoff, Lawrence H Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant gliomaHideho Okada, Pawel Kalinski, Ryo Ueda, et al.
Familial Cancer|April 10, 2021
A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancerI Kedar, L Walsh, G Reznick Levi, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Andrew B Lassman, Michael R Rossi, Jeffrey J Raizer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2012
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03Eudocia Q Lee, Vinay K Puduvalli, Joel M Reid, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
Anthropologischer Anzeiger; Bericht Uber Die Biologisch-Anthropologische Literatur|May 22, 2012
Diversity in auxology: between theory and practice. Proceedings of the 18th Aschauer Soiree, 13th November 2010M Hermanussen, L S Lieberman, V Schönfeld Janewa, et al.
Pageof 35

Showing results (331-340 of 345) with videos related to

Sort By:
Pageof 35
Frontiers in Immunology|May 24, 2021
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in GlioblastomaItay Raphael, Rajeev Kumar, Lauren H McCarl, et al.
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2016
Quantitative Imaging in Cancer Clinical TrialsThomas E Yankeelov, David A Mankoff, Lawrence H Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant gliomaHideho Okada, Pawel Kalinski, Ryo Ueda, et al.
Familial Cancer|April 10, 2021
A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancerI Kedar, L Walsh, G Reznick Levi, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Andrew B Lassman, Michael R Rossi, Jeffrey J Raizer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2012
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03Eudocia Q Lee, Vinay K Puduvalli, Joel M Reid, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
Anthropologischer Anzeiger; Bericht Uber Die Biologisch-Anthropologische Literatur|May 22, 2012
Diversity in auxology: between theory and practice. Proceedings of the 18th Aschauer Soiree, 13th November 2010M Hermanussen, L S Lieberman, V Schönfeld Janewa, et al.
Pageof 35